Amyloid‐associated increases in longitudinal report of subjective cognitive complaints

Rebecca E. Amariglio1,2, Rachel F. Buckley2,3,4, Elizabeth C. Mormino2,5, Gad A. Marshall1,2, Keith A. Johnson1,2,6, Dorene M. Rentz1,2, Reisa A. Sperling1,2
1Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
3Florey Institute, University of Melbourne, Parkville, Victoria, Australia
4Melbourne School of Psychological Sciences, University of Melbourne, Parkville, Victoria, Australia
5Department of Neurology, Stanford Medical School, Palo Alto, CA, USA
6Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Tóm tắt

AbstractIntroduction

To investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden.

Methods

Two hundred seventy‐nine clinically normal older participants (mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of community‐dwelling individuals, were followed longitudinally (4.27 ± 1.35 years) with annual subjective memory questionnaires and neuropsychological assessment. 11C Pittsburgh compound‐B positron emission tomography was used to measure cortical amyloid and to classify status (Aβ+/Aβ−) at baseline.

Results

Higher baseline SCC predicted more rapid cognitive decline on neuropsychological measures among those with elevated amyloid (t = −2.18, P < .0001). In addition, longitudinal report of SCC significantly increased over time, with SCC progression most pronounced among Aβ+ individuals (t = 2.24, P = .0005).

Discussion

SCC may inform risk for future cognitive decline and track progression of self‐perceived decline, particularly in those along the AD trajectory, providing potentially important indicators of clinical meaningfulness in AD prevention trials.


Tài liệu tham khảo

10.1016/j.jalz.2014.01.001

10.1016/j.jalz.2018.02.018

10.1016/j.neuropsychologia.2012.08.011

10.1212/WNL.0000000000001712

10.1016/j.neurobiolaging.2005.10.010

10.1016/j.biopsych.2007.05.030

10.1212/01.wnl.0000234032.77541.a2

10.1001/jamaneurol.2017.2216

10.1212/WNL.57.12.2217

10.1111/j.1532-5415.2005.53209.x

10.1037/a0020859

10.1212/WNL.0000000000002153

10.1111/j.1532-5415.2004.52568.x

10.1016/j.jalz.2015.12.013

10.1212/WNL.0b013e31826c1a8d

10.1212/WNL.0b013e3182a8418b

10.1212/WNL.0b013e3182563bbe

10.1001/jamaneurol.2014.2031

10.1212/WNL.43.11.2412-a

Wechsler D., 1987, Wechsler Memory Scale Revised Manual

10.1111/j.1532-5415.2011.03543.x

10.1177/089198879701000407

10.1001/jamaneurol.2014.803

10.1080/87565648709540361

10.1016/j.neuron.2009.07.003

10.1002/ana.22333

10.1002/ana.24546

10.1038/sj.jcbfm.9600146

10.1212/WNL.0000000000000431

10.1001/jamaneurol.2014.3375

Parisi J.M., 2011, Modeling change in memory performance and memory perceptions: findings from the ACTIVE study, Psychol Aging, 26, 518, 10.1037/a0022458

10.1017/S1355617715000922

10.1016/j.jalz.2017.12.003